Hematological Malignancies

Event Free Survival by Treatment Arm (ITT population; N=683)

%

100

90

80.1%

Rituximab maintenance Observation

80

76.5%

70

60

50

40

30

20

HR: 0.78 95% CI: 0.57-1.08

10

3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60 63 66 69 72 75 78 81 p = 0.067

0

0

Time [months]

N at risk Rituximab Observation

338 342

302 308

283 283

269 275

261 261

249 245

242 234

204 198

23 34

13 20

12 18

12 17

1 3

0

0 U Yäger et al. ICML 2013